CareDx's revenue has re-accelerated to $139.4M in 2026Q3, up 39.3% year-over-year, which suggests demand has recovered strongly from the mid-2025 slowdown and gross margin has held near 71.1%.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $0.70+174.7% vs $0.25 | $139M+14.3% vs $122M |
Q3 2026 Jul 30, 2026 | $0.37+59.4% vs $0.23 | $132M+15.7% vs $114M |
Q2 2026 Apr 28, 2026 | $0.34+209.1% vs $0.11 | $118M+15.4% vs $102M |
Q1 2026 Feb 24, 2026 | $0.12+503.0% vs $0.02 | $108M+5.0% vs $103M |
CareDx's Q3 earnings are in focus as transplant testing growth, stronger reimbursement and oncology expansion drive revenue prospects despite potential margin pressures.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) being presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 22–25 in Denver, Colorado. The findings address several persistent challenges in kidney transplant management: determining the significance of a.
On October 16, 2026, CareDx Inc (CDNA) shares fell 4.0% to $64.00, reflecting a volatile performance over the past year, with a 52-week high of $72.51 and a low
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after market close on Thursday, October 29, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of C.
Benchmark CDNA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CareDx, Inc (CDNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $78.56 | $4.06B | 33.58 | 13.79% | 25.86% | 34.08% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $2.26 | $701.96M | -5.36 | 3.89% | -81.31% | -2618.51% | — | |
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — | |
| $1.74 | $20.14M | -93.55 | 71.61% | -6.64% | -0.8% | — | |
| $23.74 | $674.23M | -7.22 | 13.83% | -27.53% | -8.8% | — |
CareDx, Inc (CDNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CareDx, Inc (CDNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
Jul 7, 2026·SEC
Get notified when CDNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CareDx, Inc (CDNA) stock FAQ — growth, dividends, profitability & financials explained
CareDx, Inc (CDNA) reported $497.4M in revenue over the trailing twelve months. Revenue was $379.8M in fiscal year 2025. That is 1757% more than the $20.5M of fiscal year 2012.
CareDx, Inc (CDNA) grew revenue by 38.9% over the trailing twelve months, compared with the twelve months before.
Yes. CareDx, Inc (CDNA) earned $128.6M in net income over the trailing twelve months (a 25.9% net margin).
CareDx, Inc (CDNA) had a return on equity (ROE) of 34.1% over the trailing twelve months. That is well above the market's typical 10-15%.
CareDx, Inc (CDNA) generated $60.1M in free cash flow over the trailing twelve months.
